Akari Therapeutics Q3 net loss narrows
AKTX•Akari Therapeutics’ third-quarter net loss narrowed to $4.8 million from $6.4 million a year earlier. The company ended the quarter with $5.7 million in cash.
1. Quarterly results
Akari Therapeutics reported a third-quarter net loss of $4.8 million, down from $6.4 million in the same period last year. Research and development expenses rose to $2.1 million as the company advanced its antibody-drug conjugate pipeline and initiated toxicology studies.
2. Pipeline plans
The company plans a Phase 1 clinical trial of AKTX-101 in mid-2027, pending additional financing. It is also pursuing strategic partnerships to expand applications for its PH1 payload platform, including a collaboration with Whitehawk Therapeutics to develop dual-payload antibody-drug conjugates.
